FDA Pathway Finder
Identify the right submission pathway in under 4 minutes.
Is your device life-supporting or life-sustaining?
Does a legally marketed predicate device exist?
What is the level of patient risk if device fails?
Engineering FDA, EU MDR/IVDR & global regulatory success — from Series-A biotech to Fortune 100 device manufacturers. Operator-grade strategy, not consultant slide-ware.
Trusted by

We are a boutique consulting firm built around a single operator with 28+ years of FDA, EU MDR, QMSR and Combination Product experience across cardiovascular, drug-delivery, IVD, biotech and digital health. We bring depth, not bench-strength inflation.
Every engagement is led personally by Leonel Vanegas. You will not be handed off to a junior associate.

Predicate strategy, eSTAR authoring, FDA correspondence — from concept to clearance.
Learn more →
Notified Body strategy, Technical Documentation per Annex II/III, PMS/PMCF infrastructure.
Learn more →
21 CFR Part 4 quality system design for drug-device and biologic-device products.
Learn more →
ISO 13485:2016 + QMSR 2026 — built, gap-assessed, and audit-ready.
Learn more →
PCCP authoring, AI Act + ISO/IEC 42001 alignment, SaMD lifecycle strategy.
Learn more →
eCTD authoring, lifecycle management, FDA / EMA / global pharmaceutical strategy.
Learn more →Free 30-min consult. We learn your product, your target markets, and your timeline.
Written regulatory strategy memo — pathways, predicates, agency interactions, risk register.
We draft your submission package (eSTAR, MDR Technical File, eCTD modules, QMS procedures).
We lead Pre-Sub, IDE, IND, and Notified Body interactions on your behalf.
Post-market surveillance, CAPA, change control — we stay engaged through commercialisation.
Identify the right submission pathway in under 4 minutes.
Is your device life-supporting or life-sustaining?
Does a legally marketed predicate device exist?
What is the level of patient risk if device fails?
Benchmark your QMS against ISO 13485 + QMSR 2026.
Do you have a documented QMS aligned to ISO 13485?
When was your last QMS internal audit?
How many open CAPAs do you currently have?
Audit your Technical Documentation against MDR Annex II.
Do you have a current Notified Body relationship?
Is your Technical Documentation MDR Annex II-compliant?
Is your PMS / PMCF infrastructure operational?
Project realistic submission timelines.
What is your target submission?
How complete is your design verification?
Will you need clinical data?
Phase-in begins 6 May 2025. Whether you stay LDT, file 510(k)/De Novo, or restructure, the time for analysis is now.
StartupsMost startup decks treat regulatory as a checkbox. Sophisticated investors want a defensible pathway, risk-tiered timeline, and a credible team. Here is a template.
LATAMBrazil and Mexico together account for 65% of LATAM medtech spend. Registering them in parallel is achievable — here is how.
Each bundle pairs the courses our clients buy together most often — designed to take you from problem statement to submitted dossier.
Hit the 2 Feb 2026 deadline with confidence.
Everything to land your drug-device submission first try.
Author, file and defend an AI/ML SaMD in 90 days.
Tell us about your program — we typically respond within one business day.
Book a free 30-min consult